康替唑胺治疗结核病的研究进展

doi:10.19982/j.issn.1000-6621.20240362

摘要/Abstract

摘要：

全球结核病防治形势不容乐观,发病率和病亡率居高不下,中国依然是全球结核病高负担国家之一。近年来,作为噁唑烷酮类药物的代表,利奈唑胺在耐药和重症结核病治疗中的应用日益广泛,因突出的抗菌疗效,其临床地位不断提升,但由于骨髓抑制、周围神经病变等不良反应的频繁发生,导致其在长疗程的结核病治疗中的应用受到了很大的限制。康替唑胺通过对利奈唑胺构效改造获得,其不良反应大大降低。近年来,越来越多的研究关注于康替唑胺在结核病治疗中的作用。本文阐述了康替唑胺治疗结核病的研究进展, 以期为临床使用康替唑胺治疗结核病提供借鉴。

关键词: 结核, 抗药性, 抗菌药, 恶唑烷酮类, 综述文献(主题)

Abstract:

The global situation of tuberculosis prevention and control is not optimistic, with high incidence rate and mortality. China is still one of the countries with high burden of tuberculosis in the world. In recent years, as the representative of oxazolidinones, linezolid has been increasingly widely used in the treatment of drug-resistant and severe tuberculosis. Due to its outstanding antibacterial effect, its clinical status has been continuously improved. However, due to the frequent occurrence of bone marrow suppression, peripheral neuropathy and other adverse reactions, its application in the long-term treatment of tuberculosis has been greatly limited. Contezolid is obtained by modifying the structure and activity of linezolid, greatly reducing its adverse reactions. In recent years, more and more studies have focused on the role of contezolid in the treatment of tuberculosis. In this paper, the research progress of contezolid in the treatment of tuberculosis was reviewed, with a view to providing reference for clinical use of contezolid in the treatment of tuberculosis.

Key words: Tuberculosis, Drug resistance, Anti-bacterial agents, Oxazolidinones, Review literature as topic

中图分类号:

王宇津, 初乃惠, 聂文娟. 康替唑胺治疗结核病的研究进展[J]. 中国防痨杂志, 2024, 46(11): 1395-1399. doi: 10.19982/j.issn.1000-6621.20240362

Wang Yujin, Chu Naihui, Nie Wenjuan. Research progress in the treatment of tuberculosis with contezolid[J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1395-1399. doi: 10.19982/j.issn.1000-6621.20240362

参考文献 34

[1]	World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[2]	Berry C, Yates TA, Seddon JA, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J, 2016, 47(5): 1591-1592. doi:10.1183/13993003.01646-2015. pmid: 27132271
[3]	Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB Treatment—2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018, 392(10150): 821-834. doi:10.1016/S0140-6736(18)31644-1. pmid: 30215381
[4]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020, 382(10): 893-902. doi:10.1056/NEJMoa1901814.
[5]	Thwaites G, Nguyen NV. Linezolid for Drug-Resistant Tuberculosis. N Engl J Med, 2022, 387(9): 842-843. doi:10.1056/NEJMe2208554.
[6]	Tse-Chang A, Kunimoto D, Der E, et al. Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review. Can J Infect Dis Med Microbiol, 2013, 24(3): e50-52. doi:10.1155/2013/535616.
[7]	Wright A, Deane-Alder K, Marschall E, et al. Characterization of the Core Ribosomal Binding Region for the Oxazolidone Family of Antibiotics Using Cryo-EM. ACS pharmacol Transl Sci, 2020, 3(3): 425-432. doi:10.1021/acsptsci.0c00041. pmid: 32566908
[8]	Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem, 2014, 57(11): 4487-4497. doi:10.1021/jm401931e. pmid: 24694071
[9]	Liu W, Yang L, Qin H, et al. Successful Treatment of Intractable Tuberculous Peritonitis in a Woman with Chronic Kidney Allograft Dysfunction Using Contezolid Containing Regimen. Infect Drug Resist, 2024, 17: 2713-2718. doi:10.2147/IDR.S465350.
[10]	Carvalhaes CG, Duncan LR, Wang W, et al. In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe. Antimicrob Agents Chemother, 2020, 64(11): e01195-20. doi:10.1128/AAC.01195-20.
[11]	Wu J, Cao G, Wu H, et al. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers. Antimicrob Agents Chemother, 2020, 64(6): e02158-19. doi:10.1128/AAC.02158-19.
[12]	Gostelow M, Gonzalez D, Smith PB, et al. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol, 2014, 7(3): 327-340. doi:10.1586/17512433.2014.909281.
[13]	包紫薇, 刘佳, 姚琳, 等. 康替唑胺在抗结核治疗中的应用前景. 抗感染药学, 2023, 20(10):1018-1024. doi:10.13493/j.issn.1672-7878.2023.10-004.
[14]	Eckburg PB, Ge Y, Hafkin B. Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects. Antimicrob Agents Chemother, 2017, 61(4): e02181-16. doi:10.1128/AAC.02181-16.
[15]	Wu X, Meng J, Yuan H, et al. Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development. Antimicrob Agents Chemother, 2021, 65(11): e0040921. doi:10.1128/AAC.00409-21.
[16]	Hoy SM. Contezolid: First Approval. Drugs, 2021, 81(13): 1587-1591. doi:10.1007/s40265-021-01576-0. pmid: 34365606
[17]	Meng J, Zhong D, Li L, et al. Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-Dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos, 2015, 43(5): 646-659. doi:10.1124/dmd.114.061747. pmid: 25710940
[18]	Wang J, Ma L. Tuberculosis patients with special clinical conditions treated with contezolid: three case reports and a literature review. Front Med(Lausanne), 2023, 10: 1265923. doi:10.3389/fmed.2023.1265923.
[19]	An H, Sun W, Liu X, et al. In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosis. Microbiol Spectr, 2023, 11(5): e0462722. doi:10.1128/spectrum.04627-22.
[20]	Shoen C, DeStefano M, Hafkin B, et al. In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2018, 62(8): e00493-18. doi:10.1128/AAC.00493-18.
[21]	Wang C, Wang G, Huo F, et al. Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in China. Front Med(Lausanne), 2022, 9: 1067516. doi:10.3389/fmed.2022.1067516.
[22]	Almeida D, Li S-Y, Lee J, et al. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. Antimicrob Agents Chemother, 2023, 67(12): e0078923. doi:10.1128/aac.00789-23.
[23]	Jiang G, Liu R, Ge Q, et al. Contezolid demonstrated equivalent efficacy to linezolid in tuberculosis treatment in an early bactericidal activity study. ESCMID Global, Barcelona, Spain, 2024.
[24]	Wang W, Voss KM, Liu J, et al. Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol, 2021, 34(5): 1348-1354. doi:10.1021/acs.chemrestox.0c00524.
[25]	Wu J, Wu H, Wang Y, et al. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis. Clin Ther, 2019, 41(6): 1164-1174.e4. doi:10.1016/j.clinthera.2019.04.025. pmid: 31126694
[26]	Wu X, Li Y, Zhang J, et al. Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects. Clin Ther, 2018, 40(2): 322-332.e5. doi:10.1016/j.clinthera.2017.12.017. pmid: 29398160
[27]	Zhao X, Huang H, Yuan H, et al. A Phase Ⅲ multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother, 2022, 77(6): 1762-1769. doi:10.1093/jac/dkac073.
[28]	Fang E, Yang H, Yuan H. Platelet Counts in Contezolid Complicated Skin and Soft Tissue Infection Phase 2 and Phase 3 Clinical Trials. Open Forum Infectious Diseases, 2022, 9(S2): ofac492.1332. doi:10.1093/ofid/ofac492.1332.
[29]	Wang J, Nie W, Ma L, et al. Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients. Infect Drug Resist, 2023, 16: 6237-6245. doi:10.2147/IDR.S425743. pmid: 37745897
[30]	Ma X, Zhang R, Cai X, et al. Plasma Concentrations of Con-tezolid and Its Efficacy and Safety in Elderly Patients with Multidrug-Resistant Tuberculosis and Renal Insufficiency. Infect Drug Resist, 2024, 17: 3047-3056. doi:10.2147/IDR.S468543.
[31]	Shi S, Feng B, Li D, et al. Treatment of Tuberculous Pleurisy With Contezolid in a Child With Glucose-6-Phosphate Dehydrogenase Deficiency: The First Case Report. Pediatr Infect Dis J, 2024, 43(9): 869-871. doi:10.1097/INF.0000000000004369.
[32]	Xu Z, Zhang J, Guan T, et al. Case report: Successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid. Front Med(Lausanne), 2023, 10: 1224179. doi:10.3389/fmed.2023.1224179.
[33]	Guo W, Hu M, Xu N, et al. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report. Int J Antimicrob Agents, 2023, 62(2): 106875. doi:10.1016/j.ijantimicag.2023.106875.
[34]	Pi R, Chen X, Meng J, et al. Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2022, 66(10): e0103422. doi:10.1128/aac.01034-22.